Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pTVG-AR Vaccine in Metastatic Prostate Cancer
NCT02411786Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Aug 2015
- Primary completion
- May 2019
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pTVG-AR in prostate cancer (PCa) (4 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Number and severity of adverse events at Week 72 and Immune Response Rate at Week 72. Started Aug 2015; status: completed.
02
Drugs
pTVG-AR
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02411786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411786.